BrightSpring Health Services, Inc.

- The company has a leverage ratio of 2.27x as of March 31, 2026, with net debt of approximately $1.7 billion. - They have received $811 million net cash proceeds before tax from the $835 million gross cash consideration for Community Living, with about $100 million in taxes expected to be paid in Q2 2026. - Management plans to remain active in evaluating options for the existing term loan and the appropriate capital structure over the coming months given strong operating performance. - There is no explicit mention of new fundraising via debt or equity in the near term during the call. - The company targets a leverage ratio under 3x (mid-2s) and prefers disciplined capital allocation, indicating openness to measured use of debt for acquisitions or initiatives if strategic.

- Investments were made in IT and other areas contributing to increased costs in Q1. - Continued investments in sales force across different businesses to drive growth. - Ongoing investments in operational efficiencies, including AI and automation tools (e.g., order intake automation, portal integrations). - Internal AI team expanded to over 20 people, focusing on technology-driven cost reductions and process improvements. - Planned additional IT projects throughout 2025 with a slight expected increase in corporate costs. - Continuous improvement initiatives (Lean Sigma training) supporting operational savings that are reinvested in people and technology. - Investments aim to support growth over the next 1-3 years and improve margins via operational efficiency. - Focus on scaling home health & hospice capabilities and value-based care models with technology integration.

- Pharmacy Solutions expected to see balanced sequential revenue and EBITDA growth throughout 2026, with year-over-year growth moderated from a strong Q1 performance. - Specialty and infusion segments showing strong double-digit script growth (+30% YoY); infusion growth driven by both acute and chronic specialty areas. - Continued generic drug conversions and new LDD wins anticipated to sustain volume growth in specialty pharmacy. - Expansion into new therapeutic areas beyond oncology underway, targeting infusion chronic specialty growth. - Fee-for-service pharmacy business growing rapidly (40-50% YoY), becoming a meaningful contributor. - Operational initiatives and technology investments expected to improve efficiency and support growth, with ongoing AI applications in workflow automation. - Home & Community Pharmacy revenue impacted by IRA but showed year-over-year profit growth excluding uneconomic customers; Q2 and beyond expected to strengthen. - Provider Services growing through census growth, de novo expansions, and acquisitions integration, continuing strong revenue momentum.

- Total revenue for 2026 is expected in the range of $14.725 billion to $15.225 billion, representing 14.1% to 17.9% growth over 2025 (excluding Community Living). - Pharmacy Solutions revenue projected between $12.85 billion and $13.3 billion. - Provider Services revenue anticipated between $1.875 billion and $1.935 billion. - Total adjusted EBITDA for 2026 expected between $795 million and $825 million, reflecting 28.7% to 33.6% growth over 2025 (excluding Community Living). - Adjusted EPS for Q1 2026 was $0.39 with profitability growth driven by operational improvements. - Investments in IT, sales force, and operational efficiencies expected to support growth and margin improvement over coming years. - Management anticipates continued quarter-over-quarter growth in revenue and EBITDA, more balanced throughout 2026. - Cash flow from operations expected to be approximately $500 million for full year 2026.

The transcript of the provided pages does not explicitly mention the current or expected orderbook or pending orders in quantitative terms. However, relevant points related to growth, demand, and business momentum include: - Specialty and infusion script growth was approximately 30% year-over-year, with specialty slightly higher and infusion in the mid-teens. - Growth driven by new accounts, prescribers, and expanded therapeutic areas beyond oncology. - Pharmacy Solutions segment revenue grew 25% year-over-year to $3.2 billion. - 5 LDDs (Limited Distribution Drugs) won in the last 6 months, expanding participation. - Fee-for-service programs including hubs and service agreements growing 40-50% year-over-year. - Infusion business showing solid volume growth. - Pricing/reimbursement dynamics with PBMs and payers stable with no big changes currently. - Investments in sales force and operational initiatives ongoing to support growth. No explicit orderbook or pending order numbers disclosed.